Valneva/$VALN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Valneva
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Ticker
$VALN
Sector
Primary listing
Employees
700
Headquarters
Website
Valneva Metrics
BasicAdvanced
$1B
-
-$0.50
1.01
-
Price and volume
Market cap
$1B
Beta
1.01
52-week high
$12.25
52-week low
$5.43
Average daily volume
115K
Financial strength
Current ratio
2.266
Quick ratio
1.476
Long term debt to equity
79.522
Total debt to equity
105.628
Interest coverage (TTM)
-2.10%
Profitability
EBITDA (TTM)
-39.244
Gross margin (TTM)
9.86%
Net profit margin (TTM)
-34.15%
Operating margin (TTM)
-25.18%
Effective tax rate (TTM)
-3.35%
Revenue per employee (TTM)
$328,780
Management effectiveness
Return on assets (TTM)
-6.58%
Return on equity (TTM)
-38.01%
Valuation
Price to revenue (TTM)
7.798
Price to book
4.44
Price to tangible book (TTM)
5.09
Price to free cash flow (TTM)
-56.933
Free cash flow yield (TTM)
-1.76%
Free cash flow per share (TTM)
-0.2
Growth
Revenue change (TTM)
25.47%
Earnings per share change (TTM)
78.90%
3-year revenue growth (CAGR)
-13.60%
10-year revenue growth (CAGR)
11.66%
3-year earnings per share growth (CAGR)
-34.59%
10-year earnings per share growth (CAGR)
7.65%
Bulls say / Bears say
EMA lifts temporary restriction on Ixchiq for adults 65+, restoring use in a high-risk demographic after safety review and expanding EU market potential (Reuters)
Exclusive distribution partnership with CSL Seqirus in Germany secures marketing of IXCHIQ from July 2025 and IXIARO/DUKORAL from January 2026, leveraging partner’s strong footprint in Europe’s largest travel vaccine market (Nasdaq)
Potential blockbuster pipeline catalyst: Phase 3 data readout for the VLA15 Lyme disease vaccine candidate is expected by end-2025, offering a pathway to >$1 billion annual sales and major value inflection (Barron’s)
FDA suspension of Ixchiq license in the U.S. forces an immediate halt to chikungunya vaccine distribution, risking loss of over 8% of H1 product sales and potential long-term exclusion from the U.S. market (Reuters)
Persistent unprofitability: Valneva recorded a net loss of €20.8 million and an adjusted EBITDA loss of €6.0 million in H1 2025 despite a 37.8% revenue increase, highlighting continued cash burn and expense pressures (Ainvest)
Key pipeline outcomes delayed: even if Phase 3 VLA15 Lyme disease data are positive, regulatory submissions and approvals are unlikely before 2026, deferring meaningful revenue diversification beyond travel vaccines (Barron’s)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
Valneva News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Valneva stock?
Valneva (VALN) has a market cap of $1B as of October 06, 2025.
What is the P/E ratio for Valneva stock?
The price to earnings (P/E) ratio for Valneva (VALN) stock is 0 as of October 06, 2025.
Does Valneva stock pay dividends?
No, Valneva (VALN) stock does not pay dividends to its shareholders as of October 06, 2025.
When is the next Valneva dividend payment date?
Valneva (VALN) stock does not pay dividends to its shareholders.
What is the beta indicator for Valneva?
Valneva (VALN) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.